Dr. Videlis Nduba
Consultant
MD, PhDAbout Me:
Dr. Videlis Nduba, MD, PhD, is a centre director at the Centre for Respiratory Diseases Research, Kenya Medical Research Institute, in Nairobi, Kenya. As a medical officer from Kenya and epidemiologist trained at the school of public health at the University of Washington, Seattle, he started his career working in HIV and eventually transitioned to respiratory diseases. He has 18 years of clinical trials experience and has conducted multiple trials in tuberculosis vaccines, TB drug trials, sickle cell disease, and malaria drug trials.
Education:
| Year | Degree | Institute |
|---|---|---|
| 2008 | PhD | |
| Master’s Degree in public health | University of Washington | |
| 1999 | medical school |
The center director at the Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI)
| Year | Department | Position | Hospital |
|---|---|---|---|
Dr. Videlis Nduba, MD, PhD, is a center director at the Centre for Respiratory Diseases Research, Kenya Medical Research Institute, in Nairobi, Kenya. As a medical officer from Kenya and epidemiologist trained at the school of public health at the University of Washington, Seattle, he started his career working in HIV and eventually transitioned to respiratory diseases. He has 18 years of clinical trials experience and has conducted multiple trials in tuberculosis vaccines, TB drug trials, sickle cell disease, and malaria drug trials.
Dr. Videlis’s work focusing on TB Research including developing tuberculosis epidemiological capacity to conduct phase II and III TB vaccine trials in adolescents and infants, diagnostics for infant TB, and epidemiology of TB in adolescents. He was a principal investor of a double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402) in infants, of which Kenya was one of four countries participating in this trial.
Dr. Nduba has conducted two TB vaccine trials, one in infants and the other in adults that included bio banking protocols and extensive immunology sample collection and processing.
He has also lead a TB drug treatment trial that examined at a novel new treatment- MPaZ for shortening TB treatment from six to four months for drug sensitive TB. This research has included developing extensive networks with the TB treatment program, community networks with TB ambassadors and community health.